HLVX Stock Overview
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HilleVax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.02 |
| 52 Week High | US$20.22 |
| 52 Week Low | US$9.94 |
| Beta | 0 |
| 1 Month Change | -24.12% |
| 3 Month Change | -21.69% |
| 1 Year Change | -15.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.04% |
Recent News & Updates
Shareholder Returns
| HLVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 0.4% | 1.0% |
| 1Y | -15.4% | 0.9% | 21.9% |
Return vs Industry: HLVX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: HLVX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| HLVX volatility | |
|---|---|
| HLVX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HLVX's share price has been volatile over the past 3 months.
Volatility Over Time: HLVX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 90 | Rob Hershberg | www.hillevax.com |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. Fundamentals Summary
| HLVX fundamental statistics | |
|---|---|
| Market cap | US$578.75m |
| Earnings (TTM) | -US$123.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs HLVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$123.57m |
| Earnings | -US$123.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 9.5% |
How did HLVX perform over the long term?
See historical performance and comparison